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Aims: This study assessed the cost-effectiveness of long-acting insulin analogues
(LAIAs) vs intermediate/long-acting human insulin (ILAHI) for patients with type 1 dia-
betes (T1D) in real-world clinical practice.
Methods: Individual-level analyses were conducted within a longitudinal population-
based cohort of 540 propensity score-matched T1D patients (LAIAs, n = 270; ILAHI,
n = 270) with over 10 years of follow-up using Taiwan's National Health Insurance
Research Database, 2004–2013, from third-party payer and healthcare sector per-
spectives. The study outcomes included the number needed to treat (NNT) to pre-
vent one case of clinical events (eg, hypoglycaemia, diabetes-related complications),
medical costs, and cost per case of events prevented. Cost estimates are presented
in 2013 British pounds (GBP, £).
Results: The NNTs using LAIAs vs ILAHI to avoid one case of hypoglycaemia requir-
ing medical assistance, outpatient hypoglycaemia and any diabetes-related complica-
tions were 12, 9 and 10 for mean follow-up periods of 5.84, 6.02 and 3.62 years,
respectively. From third-party payer and healthcare sector perspectives, using LAIAs
instead of ILAHI saved GBP6924-GBP7116 per case of hypoglycaemia requiring
medical assistance prevented, GBP5346-GBP5508 per case of outpatient
hypoglycaemia prevented, and GBP3570-GBP3680 per case of any diabetes-related
complications prevented. Sensitivity analyses considering sampling uncertainty
showed that using LAIAs over ILAHI yields at least a 76% probability of cost-saving
for avoiding one case of hypoglycaemia requiring medical assistance, outpatient
hypoglycaemia or any diabetes-related complications.
Conclusions: This real-world evidence reveals that compared with ILAHI, the greater
pharmaceutical costs associated with LAIAs for patients with T1D could be substan-
tially offset by savings from averted hypoglycaemia or diabetes-related
complications.
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1 | INTRODUCTION
Type 1 diabetes (T1D) is associated with an increased risk of vascular
complications compared with the non-diabetic population.1-3 The
morbidity and mortality associated with diabetes have resulted in a
substantial economic burden on national healthcare.4 In 2009, the
estimated number of patients with T1D in Taiwan was 8043, which
accounts for less than 1% of the diabetic population; the age-
standardized incidence rate was 31.3 per million persons.5 Although
T1D accounts for a small proportion of the diabetic population, it
leads to a substantial economic burden in Taiwan. Our previous study
showed that T1D was associated with lifetime healthcare expendi-
tures of British Pounds (GBP, £) 65 158 per case in Taiwan.6 More-
over, the annual healthcare costs per case for patients with T1D were
estimated to be 1.5 to 3 times greater than those for patients with
type 2 diabetes according to studies from the United States.7,8
Patients with T1D typically require multiple-dose insulin injec-
tions to mimic the natural secretory pattern of insulin in the body.
Long-acting insulin analogues (LAIAs) have better pharmacokinetic
and pharmacodynamic profiles,9-12 resulting in a slight reduction in
glycosylated hemoglobin (HbA1c) (less than 0.5%) and a lower risk of
hypoglycaemia compared with those for intermediate/long-acting
human insulin (ILAHI) (eg, neutral protamine Hagedorn; NPH).13 How-
ever, the price of LAIAs (ie, insulin glargine, insulin detemir) is four
times higher than that of NPH according to Taiwan's National Health
Insurance (NHI) price listings.14 The economic value of LAIAs is
debated15,16 because of their high acquisition costs compared with
that of ILAHI and the uncertainty of their effectiveness in improving
solid clinical outcomes (eg, diabetes-related complications). Patients'
age and treatment convenience could be important factors influencing
clinicians' decisions in selecting LAIA vs ILAHI for patients with T1D in
Taiwan. Specifically, for young children with T1D who are unable to
use injectable insulin by themselves at school, it is more convenient
for their parents to use a regimen of ILAHI and short-acting insulin
twice daily (ie, before and after school). Older children, adolescents
and adult patients with T1D are likely to be prescribed a four-times-
daily regimen with LAIA once daily and rapid-acting insulin three times
daily to reduce the risk of hypoglycaemia.
Although several cost-effectiveness studies of LAIAs vs ILAHI
among patients with T1D exist, the results remain inconclusive and no
such study has been done in Taiwan. Studies have shown that some
LAIAs (ie, glargine,17,18 detemir19-23 and degludec23) are more costly
but also more effective than ILAHI, with a large variation in incremen-
tal cost-effectiveness ratio estimates, from GBP2562 to GBP99 683
per quality-adjusted life year, while others (ie, glargine24 and
detemir25) are cost-saving compared to ILAHI. Moreover, the results
from previous studies17-25 should be interpreted with caution. First,
the model inputs in the model-based simulation studies were typically
taken from a single clinical trial with limited sample size and follow-up
time.17-22,24,25 However, the efficacy data from clinical trials may not
translate to clinical effectiveness/outcomes. The model inputs directly
taken from clinical trials may not be generalizable to patients in a real-
world setting because available treatments and recommended
strategies may differ by country, and the risk equations, utilities,
resource utilization and costs may be subject to change. For example,
adherence to treatment in a real-world setting is often lower than that
observed in clinical trials. Second, the projection of long-term out-
comes (eg, incidence of diabetes-related complications) is usually done
using short-term results based on clinical biomarkers (eg, HbA1c) due
to a lack of effectiveness data from real-world settings.17-25 However,
the extrapolation from clinical biomarkers to clinical events in cost-
effectiveness analysis (CEA) should be done with caution. Third, the
results of CEA depend on the willingness-to-pay (WTP) threshold
made by health policy decision-makers, which varies by country and
healthcare setting. These limitations highlight the importance of
conducting CEA in a real-world setting from various perspectives to
corroborate previous study findings.
Against this background, we estimated the real-world cost-
effectiveness of LAIAs vs ILAHI among patients with T1D in Taiwan.
Real-world evidence provides valuable information to complement the
evidence from randomized controlled trials,26 and it has increasingly
appeared in recent studies of diabetes.27-30 The effectiveness inputs
in this CEA were based on our published comparative effectiveness
study of basal insulins, in which reduced risks of hypoglycaemia and
diabetes-related complications associated with LAIAs vs ILAHI were
found.29 The individual-level cost estimates were measured using
Taiwan's National Health Insurance Research Database (NHIRD),
which includes nationwide, population-based, longitudinal data.
What is already known about this subject
• Long-acting insulin analogues (LAIAs) yield better efficacy
in glycaemic control and reduce the risk of hypoglycaemia
relative to intermediate/long-acting human insulin (ILAHI)
in clinical trials. In a real-world setting, however, few
studies have demonstrated the effectiveness of LAIAs in
preventing long-term diabetes-related complications and
it remains unknown whether the high costs of LAIAs
could be justified against their potential effectiveness
compared with ILAHI.
What this study adds
• In a real-world setting, the high costs of LAIAs could be
justified based on their effectiveness compared with
ILAHI under a single-payer healthcare system.
• Based on the empiric data analysis from a nationwide
claims database in Taiwan, LAIAs relative to ILAHI saved
GBP852 and GBP876 per patient from third-party payer
and healthcare sector perspectives, respectively, over a
mean follow-up of 7.2 years.
• LAIAs should be considered as an economically reason-
able first-line choice for the basal insulin regimen in the
treatment of patients with type 1 diabetes.
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2 | METHODS
2.1 | Data source
This study was approved by the Institutional Review Board of National
Cheng Kung University Hospital (B-EX-103-015). This CEA utilized the
claims data of a nationwide diabetes cohort to examine the long-term
effectiveness and cost consequences of basal insulins. Specifically,
individual-level data were obtained from the Longitudinal Cohort of Dia-
betes Patients (LHDB) 2004–2013 from the NHIRD, which contains
emergency, outpatient, inpatient, and pharmacy claims. Taiwan's NHI is a
single-payer, universal-access healthcare system that was introduced in
1995 and covers over 99% of Taiwan's population.31,32 The application
of the LHDB is described in detail elsewhere.29,33
2.2 | Description of study cohort
Patients who had an ICD-9-CM diagnosis code of T1D (250.X1 or 250.
X3) and were issued a Catastrophic Illness Card (CIC) for T1D were iden-
tified in the LHDB. We further excluded those who were prescribed with
oral antidiabetic agents (except for metformin and thiazolidinediones)
after the CIC for T1D was issued and those who had a history of chronic
diabetes-related complications (ie, cardiovascular disease, nephropathy,
neuropathy and retinopathy). Among patients identified as T1D, those
who were newly prescribed with basal insulins (ie, LAIAs or ILAHI) and
had persistent use of the basal insulin (ie, at least three refills with any
gaps between two consecutive refills of fewer than 180 days) between
2004 and 2008 were included in the analyses. The propensity score (PS)-
matching method was then applied to identify baseline comparable users
of LAIAs (n = 270) with those on ILAHI (n = 270). The follow-up period
for each study patient started from the first prescription of basal insulins
until the occurrence of a diabetes-related complication, dropout from Tai-
wan's NHI program, death or the end of 2013, whichever came first, for
the effectiveness estimates, and until dropout from Taiwan's NHI pro-
gram, death or the end of 2013, whichever came first, for the cost esti-
mates. After applying the PS-matching method, all baseline characteristics
were comparable between the LAIA and ILAHI groups (mean age of each
group was 18 years old). More details about the cohort extraction proce-
dure, patient characteristics before and after PS matching and compara-
tive effectiveness results of basal insulins can be found elsewhere.29
2.3 | Study method
As recommended by the Second Panel on Cost-Effectiveness in
Health and Medicine,34 the structure of the study methods is summa-
rized in an Impact Inventory, consisting of potential effectiveness and
cost consequences of basal insulins for the third-party payer (payer
hereafter) and healthcare sector perspectives (Supplementary Table 1).
For each perspective, we measured the effect of basal insulins on
health outcomes in terms of the number needed to treat (NNT) for
preventing diabetes-related complications and all direct medical costs,
including future diabetes-related and -unrelated medical costs paid by
a third-party payer and the copayment (for healthcare sector perspec-
tive). For each study patient, we measured their direct medical costs
during the follow-up, which represented the expenditures for all medi-
cal services and products associated with medical management of
their diseases paid by Taiwan's NHI program (eg, costs of emergency
department visits, hospitalization, outpatient care, laboratory tests
and medications) and the out-of-pocket expense paid by patients. The
reporting of this study follows the Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) statement (Table S2).
2.4 | Effect of basal insulins on health outcomes
The effectiveness of basal insulins was defined as the NNT for
preventing one case of diabetes-related complications (ie, cardiovas-
cular disease [CVD], nephropathy, retinopathy, neuropathy, hospital-
ized hyperglycaemia, any hypoglycaemia requiring medical assistance,
outpatient hypoglycaemia and hospitalized hypoglycaemia) or all-
cause death. NNT measures were estimated using Equations (1)–(3).
First, we converted the incidence rates of diabetes-related complica-
tions obtained from our published study29 into cumulative incidences
using Equation (1)35:
CI = 1−e− IR× t ð1Þ
where t denotes the average observational period for each outcome
of interest among the study cohort, CI is the cumulative incidence of
the outcome of interest during time t and IR is the incidence rate of
the outcome of interest measured during time t. Second, absolute risk
reduction (ARR) was measured as the difference in the cumulative
incidences of the outcome of interest during time t between the LAIA
group (CI1) and the ILAHI group (CI0) (Equation (2)). NNT was then
estimated as 1 divided by the ARR (Equation (3)). For three outcomes
in which a statistically significant difference in risks was found
between the LAIA and ILAHI groups (ie, hypoglycaemia requiring
medical assistance, outpatient hypoglycaemia and any diabetes-
related complications), we calculated the 95% confidence intervals
(CIs) using the Wald method.36
ARR=CI0−CI1 ð2Þ
NNT=1=ARR=1= CI0−CI1ð Þ ð3Þ
2.5 | Medical costs
Each of the medical costs listed in the impact inventory was measured as
a summary of cost components from the following claims files in Taiwan's
NHIRD: emergency department, inpatient admission, outpatient visit and
pharmacy. Cost components in these claims files include the costs of
diagnosis, treatments (ie, examinations, procedures and special materials),
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pharmaceutical services and medications. In Taiwan, copayments are typi-
cally required for patients but can be waived for patients with cata-
strophic diseases such as T1D.37,38 In this study, copayments were
considered as the out-of-pocket (OOP) expense paid by patients. In the
analyses from the third-party payer perspective, we included all medical
services and costs during the follow-up related to the emergency room,
outpatient, inpatient and pharmacy components but excluded the OOP
expense. In the analyses from the healthcare sector perspective, we also
included the OOP expense.
To adjust for differences in baseline medical costs (ie, one
year before the beginning of basal insulin therapy) for LAIA and
ILAHI users, a regression-based adjustment was performed
(Equation (4))39:
costj = α+ βbaseline × costbaseline j + βtreatment × treatmentj ð4Þ
Total medical cost (costj) for a given patient j is an explanatory
variable, and baseline cost (costbaselinej) and basal insulin group
(treatmentj = 1 for the LAIA group and treatmentj = 0 for the ILAHI
group) are independent variables.
We used log-transformation to reduce the skewness of cost data
and to improve the normality of our data. We then calculated the





−βbaseline × ln costbaselinej
 
− ln costmean at baselineð Þ
 
ð5Þ
where costadjustedj is the adjusted total medical cost for a given person
j, βbaseline is the beta coefficient for baseline cost (ie, costbaselinej)
obtained from Equation (4), and costmean at baseline is the mean baseline
cost for all patients from the study cohort.
All cost estimates were standardized to the year 2013 using the
Taiwan consumer price index (https://eng.stat.gov.tw/public/data/
dgbas03/bs3/english/cpiidx.xls) and converted to 2013 GBP using an
average exchange rate of GBP1:NT$46.4 from 2013.
2.6 | Cost-effectiveness analysis of basal insulins
NNT is a measure of treatment effectiveness and is interpreted as the
average number of patients with T1D who would need to be treated with
LAIA relative to ILAHI for a given follow-up period of time to prevent
one case of diabetes-related complications or all-cause death. A lower
absolute value of NNT indicates a more effective intervention. The incre-
mental costs refer to the difference in the average per-patient medical
costs during the given follow-up period between the LAIA and ILAHI
groups. Thus, cost-effectiveness analyses were performed by multiplying
the estimates of incremental costs between LAIAs and ILAHI by the NNT
for a given study outcome from the payer and healthcare sector perspec-
tives. The incremental cost-effectiveness ratio (ICER) was estimated as
the incremental cost per one case of outcomes of interest prevented
when LAIAs are used compared with ILAHI. Because NNT is intrinsically
understandable and often used as a decision tool by clinicians, and can
conveniently be combined with costs to calculate cost-effectiveness, it
has become increasingly used as a tool in health economic evaluation
studies, including those on chronic diseases such as diabetes, cancer,
heart failure, atrial fibrillation, psoriasis and rheumatoid arthritis.40-50
Moreover, the inclusion of NNT increases clinical relevance and the appli-
cation of CEA results, and an increased understanding of the
relationships between CEA and NNT may help clinicians apply CEA find-
ings in practice.40








NNTILAHI LAIA ILAHI LAIA Overall ILAHI LAIA HR (95% CIs)
CVD 5.2 1.6 7.15 7.13 7.14 0.0363 0.0111 0.304 (0.084–1.106) 40
Nephropathy 23.7 24.3 6.72 6.55 6.64 0.1455 0.1490 1.027 (0.673–1.568) −284
Retinopathy 64.1 58.5 5.66 5.64 5.65 0.3039 0.2813 0.918 (0.689–1.223) 44
Neuropathy 15.6 18.5 6.90 6.61 6.76 0.0999 0.1173 1.169 (0.710–1.925) −57
Hospitalized hyperglycaemia 54.0 49.4 5.96 5.77 5.87 0.2717 0.2517 0.910 (0.670–1.237) 50
Hypoglycaemia that requires
medical assistance
61.8 41.7 5.63 6.04 5.84 0.3029 0.2160 0.681 (0.498–0.930) 12
Outpatient hypoglycaemia 56.6 33.0 5.76 6.28 6.02 0.2886 0.1804 0.592 (0.424–0.828) 9
Hospitalized hypoglycaemia 7.4 12.0 7.05 6.76 6.91 0.0495 0.0798 1.622 (0.830–3.170) −33
Any diabetes-related complicationsb 224.7 169.8 3.46 3.77 3.62 0.5564 0.4589 0.782 (0.639–0.956) 10
All-cause death 2.0 1.0 7.27 7.16 7.22 0.0146 0.0074 0.502 (0.092–2.739) 140
Abbreviations: CIs, confidence intervals; CVD, cardiovascular disease; HR, hazard ratio; ILAHI, intermediate/long-acting human insulin; LAIA, long-acting
insulin analogue; NNT, number needed to treat.
aIncidence rates are presented as patient number per 1000 person-years.
bAny diabetes-related complications consisted of CVD, nephropathy, retinopathy, neuropathy, hospitalized hyperglycaemia or hypoglycaemia that requires
medical assistance.
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2.7 | Sensitivity analysis
To capture the sampling uncertainty in the ICER estimates, the non-
parametric bootstrap method was applied to generate 1000 replicated
estimates of incremental cost-effectiveness pairs51 for the study sub-
jects. The 95% CIs for ICER were defined as the 2.5th and 97.5th
ranked ICER of the 1000 replicated estimates. A summary measure of
the joint uncertainty of costs and effectiveness has been presented as
cost-effectiveness acceptability curves (CEACs), which indicate the
probability of cost-effectiveness at various WTP thresholds.52
According to the World Health Organization,53 an intervention strat-
egy is considered cost-effective if the ICER is less than three
times the gross domestic product (GDP) per capita (ie, GBP41 943 in
Taiwan, 201354), and it is considered highly cost-effective if the ICER
is less than one GDP per capita (ie, GBP13 981 in Taiwan, 2013). Fur-
thermore, we performed several sensitivity analyses to estimate the
ICER based on the scenarios considered in our published effective-
ness study29: (1) the effectiveness estimates were derived from the
intention-to-treat (ITT) analysis (ie, the observation of individual
patients was stopped/censored if patients died, withdrew from Tai-
wan's NHI or at the end of 2013, whichever came first) and the cost
calculation was based on the ITT analysis with consideration of the
occurrence of the event of interest as the censoring variable, (2) both
the effectiveness and cost estimates were derived from the on-
treatment (OT) analysis (ie, the observation of individual patients was
stopped/censored if patients died, withdrew from Taiwan's NHI, at
the end of 2013, or the treatment pattern changed [ie, switch or
discontinuation], whichever came first) and (3) the effectiveness esti-
mates were derived from the OT analysis and the cost calculation was
based on the OT analysis with consideration of the occurrence of the
event of interest as the censoring variable.
3 | RESULTS
3.1 | Effectiveness estimates
Our effectiveness study revealed that compared with ILAHI, LAIAs led to
a significantly lower risk of hypoglycaemia and any diabetes-related com-
plications.29 Relative to ILAHI, 12, 9 and 10 patients (95% CIs 6 to
75, 6 to 27 and 6 to 74, respectively) would need to be treated with
LAIAs for a mean of 5.84, 6.02 and 3.62 years to prevent a case of
hypoglycaemia requiring medical assistance, outpatient hypoglycaemia
and any diabetes-related complications, respectively (Table 1).
3.2 | Cost estimates
Table 2 outlines the disaggregated cost estimates per patient for LAIA
and ILAHI users. The adjusted total cost per patient for LAIAs was
lower than that for ILAHI, with a difference of –GBP852 per patient
from the payer perspective and –GBP876 from the healthcare sector
perspective, over a mean follow-up of 7.2 years. The cost differences
were mainly due to differences in outpatient care and inpatient care.
The cost estimates for medications are shown in Table S3. The cost of
antidiabetic drugs per patient among the users of LAIAs was higher
than that for ILAHI users, which was most likely due to the higher
acquisition costs of LAIAs. However, the costs of other medications
per patient were much lower in the LAIA group vs the ILAHI group. As
a result, the overall medication cost per patient in the LAIA group was
GBP552 less than that in the ILAHI group.
3.3 | Costs per case of event prevented
The incremental costs of the average medical costs per patient per
year between the LAIA and ILAHI users were calculated from the
TABLE 2 Disaggregated results of costs per patient over







Third-party payer costs 9427 8183 −1244
Third-party payer costs (adjusteda) 8852 8000 −852
Healthcare sector perspective
Emergency costs 231 226 −4
Diagnosis 54 50 −4
Treatment 156 154 −2
Pharmaceutical service 4 4 0
Medication 16 19 3
Outpatient costs 6908 5751 −1156
Diagnosis 795 692 −102
Treatment 2049 1550 −500
Pharmaceutical service 127 115 −12
Medication 3937 3395 −542
Inpatient costs 1511 1235 −276
Room 499 407 −92
Diagnosis 114 112 −1
Therapy and examination 506 469 −38
Pharmaceutical service 30 22 −7
Medication 309 181 −128
Special material 53 44 −9
Pharmacy costs 977 1147 171
Pharmaceutical service 34 31 −3
Medication 510 626 116
Special material 433 490 57
Out-of-pocket expense 199 177 −22
Healthcare sector costs 9626 8360 −1266
Healthcare sector costs (adjusteda) 9061 8186 −876
Abbreviations: ΔC, difference in costs per case between LAIA and ILAHI
users; ILAHI, intermediate/long-acting human insulin; LAIA, long-acting
insulin analogue.
aAdjusted for baseline difference in medical costs between insulin groups.
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payer (–GBP99) and healthcare sector (–GBP102) perspectives
(Table S4). The base-case analysis demonstrates that using LAIAs vs
ILAHI is cost-saving in terms of preventing one case of hypoglycaemia
requiring medical assistance, outpatient hypoglycaemia and any
diabetes-related complications (Table 3). For example, relative to
ILAHI, 10 patients would need to be treated with LAIAs for 3.62 years
to prevent one case of any diabetes-related complications, which
would save GBP3570 and GBP3680 per case from the payer and
healthcare sector perspectives, respectively.
Using the nonparametric bootstrapping method, the 95% CIs for esti-
mated incremental costs were between –GBP2927 and –GBP1003 from
the payer perspective and between –GBP3158 and –GBP809 from the
healthcare sector perspective. The CEACs in Figure 1 indicate that the
probabilities that LAIAs are cost-saving compared with ILAHI from the
payer perspective (healthcare sector perspective) is 76.9% (77.3%), 76.8%
(77.2%) and 76.5% (76.9%), respectively, for avoiding one case of
hypoglycaemia requiring medical assistance, outpatient hypoglycaemia
and any diabetes-related complications. Using one GDP per capita (ie,
GBP13 981) as the WTP threshold, there was a 96.6–98.6% probability
that LAIAs are highly cost-effective for preventing one case of these clini-
cal events from the payer and healthcare sector perspectives. The results
from several scenario sensitivity analyses shown in Tables S5–S11 dem-
onstrate that LAIAs are either cost-saving or highly cost-effective com-
pared with ILAHI, which is consistent with the findings from base-case
analyses.
4 | DISCUSSION
This is the first real-world CEA of LAIAs vs ILAHI based on the com-
parative effectiveness results obtained from a large population-based
cohort study of T1D in a real-world setting. Relative to ILAHI, LAIAs
for patients with T1D are cost-saving for preventing one case of
hypoglycaemia requiring medical assistance, outpatient
hypoglycaemia and any diabetes-related complications, mainly owing
to the reductions in outpatient and inpatient costs. LAIAs are highly
cost-effective, with an almost 100% likelihood of falling below one
GDP per capita for Taiwan (GBP13 981).
Although a direct comparison of our study with existing cost-
effectiveness studies17-25 may be a challenge due to the use of
different analytic approaches, study perspectives and healthcare set-
tings, this real-world, population-based cost-effectiveness research
provides supporting data for favourable economic outcomes using
LAIAs vs ILAHI in patients with T1D. In particular, our analyses were
based on clinical data derived from a large population-based cohort
study with long-term follow-up on a varied range of diabetes-related
complications and all-cause death. Our study allows a sufficient time
horizon to measure relevant health impacts and costs, which is rarely
the case in trial-based cost-effectiveness studies. Moreover, we
utilized Taiwan's NHIRD, which is a data source with a nationwide
representative population, for a comprehensive estimation of all eco-
nomic consequences of treatments reimbursed by Taiwan's NHI for
TABLE 3 Results of cost-effectiveness analysis of long-acting insulin analogues vs intermediate/long-acting human insulin
Event of interest NNT
Mean follow-up
time (years)b
ΔC over mean follow-up timec
Costs per case with event of interest










CVD 40 7.14 −705 −725 −28 200 −29 000
Nephropathy −284 6.64 −656 −675 186 304 191 700
Retinopathy 44 5.65 −558 −574 −24 552 −25 256
Neuropathy −57 6.76 −667 −687 38 019 39 159
Hospitalized hyperglycaemia 50 5.87 −580 −596 −29 000 −29 800
Hypoglycaemia that requires
medical assistancea
12 5.84 −577 −593 −6924 −7116
Outpatient
hypoglycaemiaa
9 6.02 −594 −612 −5346 −5508
Hospitalized
hypoglycaemia
−33 6.91 −682 −702 22 506 23 166
Any diabetes-related
complicationa,d
10 3.62 −357 −368 −3570 −3680
All-cause death 140 7.22 −713 −734 −99 820 −102 760
Abbreviations: ΔC, difference in costs per case between LAIA and ILAHI users; CVD, cardiovascular disease; NNT, number needed to treat.
aCompared with ILAHI use, LAIA use was associated with a significantly lower risk of these events.
bThe follow-up period of time per person for each event of interest started from the first prescription of basal insulins until occurrence of an event,
withdrawal from Taiwan's NHI program, death or the end of 2013, whichever came first.
cAverage difference in the cost per patient per year between LAIA and ILAHI users is estimated in detail in Table S4.
dAny diabetes-related complications consisted of CVD, nephropathy, retinopathy, neuropathy, hospitalized hyperglycaemia or hypoglycaemia that requires
medical assistance.
Note: All cost estimates are in 2013 GBP.
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individuals with T1D. A cost analysis study of basal insulins for T1D in
a real-world setting was previously conducted using Germany's claims
database,55 but a CEA was not performed and the cost
estimates were based on only a 1-year period. The study
demonstrated a trend of lower annual costs for insulin glargine users
owing to the lower costs of bolus insulin, blood glucose test strips,
lancets, needles and antihypoglycaemic treatments vs NPH users. The
results of this short-term cost analysis are consistent with our findings
that LAIAs have higher acquisition costs, but other relevant medical
costs for LAIA users (Tables 2 and S3) are lower than those for ILAHI
users, therefore the lower economic burden associated with the use
of LAIAs vs ILAHI may be partly due to lower medical resource con-
sumption (eg, examinations, other treatments) in the short term and
lower risks of diabetes-related complications in the long term.
Several limitations in our study need to be addressed. First, our
analysis did not include direct nonmedical costs (eg, transportation
costs) and indirect costs (eg, lost productivity for individuals) due to
data unavailability, and thus the results of this study may not be
extrapolated to a societal or individual patient's perspective. Second,
the costs of lancets and blood glucose meters were not estimated
because such materials are not reimbursed by Taiwan's NHI. How-
ever, we estimated the costs of needles and test strips, which
accounted for most of the costs related to self-monitoring of blood
glucose. Third, degludec, an ultra-long-acting insulin analogue, was
not included in our analyses because it was unavailable in Taiwan in
the study period. Fourth, some diabetes-related complications could
greatly reduce a person's quality of life and thus should be considered
in a cost-utility analysis. However, due to a lack of representative util-
ity data for Taiwanese patients with T1D, a cost-utility analysis was
not conducted. Fifth, including NNT in CEA studies may increase the
understanding and relevance of CEA findings to clinical decision-
makers, but we acknowledge its limitations.56 For instance, our study
used NNT to quantify the treatment effectiveness as a function of the
difference in the probability of developing an outcome event between
two treatment groups, which can only measure one type of benefit
(eg, any diabetes-related complications in the present study) at one
time. In future studies, a survival analysis that estimates the area
under survival curves between two treatment groups could be used
to measure the aggregated benefit (eg, quality-adjusted life years
gained), which would provide a more comprehensive measure to
account for treatment benefits. Sixth, this study was based on a PS-
matched cohort that consisted of two comparable drug groups
(ie, LAIA and ILAHI), while some unmatched subjects who were
treated with LAIA or ILAHI may not be included in the analyses.57,58
Our study results therefore may limit the generalizability to those
matched patients treated with LAIA or ILAHI. Seventh, although we
found a comparable prescription refill pattern of insulins between the
two study groups, we did not account for patients' adherence behav-
iour for insulin therapy in this economic analysis study. This is because
the claims-based data did not reveal the detailed information of insu-
lin dosages that patients actually consumed. Moreover, our published
comparative-effectiveness cohort study that was used to generate the
effectiveness input parameters for this economic analysis study had
implemented two procedures to minimize the potential impact from med-
ication non-adherence.29 First, our study only included the stable users
for insulin therapy, defined as at least three consecutive refills from the
same insulin group among the first five prescriptions after initiation of
LAIA or ILAHI and any gaps between two consecutive refills less than
180 days. Second, our sensitivity analysis also examined the result of eco-
nomic analysis that was based on the effectiveness parameters which
were generated from the “as-treated” scenario, where study patients
who discontinued insulin therapy were censored in the analyses. Finally,
the results of this study may only reflect T1D patients under a single-
payer system and universal healthcare insurance coverage.
We provided real-world evidence that the use of LAIAs vs ILAHI
has a high likelihood of being cost-saving for patients with T1D to
avoid hypoglycaemia and diabetes-related complications from the
third-party payer and healthcare sector perspectives in Taiwan. LAIAs
should be considered as an economically reasonable first-line choice
for a basal insulin regimen for the treatment of patients with T1D. We
expect that the results of this study will inform clinical professionals
and health policymakers when prioritizing treatment strategies for
patients with T1D given limited healthcare resources.
F IGURE 1 Cost-effectiveness acceptability curves using 1000
bootstraps (cost estimates are in 2013 GBP) (A) from the third-party
payer perspective and (B) from the healthcare sector perspective
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